Treeline Biosciences, Inc.

Treeline Biosciences, Inc. is a US-based biotech firm dedicated to developing innovative therapeutics for cancer and other serious diseases, leveraging advances in biology, chemistry, and computational sciences. Founded in 2021 in Watertown, US, Treeline Biosciences, Inc. specializes in creating targeted therapies for serious diseases.

The company raised USD 421. 78 mn in its most recent funding round in October 2024, contributing to a total of USD 421. 78 mn raised to date. Josh Bilenker serves as the CEO, and the company has completed 3 deals since its inception.

Treeline Biosciences focuses on developing innovative therapeutics to address cancer and other serious diseases. Its pipeline includes diverse drug candidates that target specific disease mechanisms, offering potential solutions for various cancer forms. The internal development team collaborates with external contract research organizations (CROs) to enhance capabilities and scale operations. The company's products are aimed at markets in North America and Europe, targeting healthcare providers and research institutions.

Treeline Biosciences operates in the biotech sector, engaging in revenue-generating activities through partnerships and funding initiatives. Revenue is anticipated from collaborations with healthcare investors and strategic partners, involving investments for equity stakes or milestone payments tied to clinical development. Additionally, revenue may arise from licensing agreements for proprietary drug candidates or partnerships with pharmaceutical companies for co-development of therapies. In August 2025, Treeline Biosciences, Inc.

raised USD 200 million in series A funding from new investors AI Life Sciences Investments, Exor Ventures, Fidelity Investments, and T Rowe Price, with participation from returning investors Aisling Capital, Ajax Health LLC, ARCH Venture Partners, Casdin Capital, GV, KKR, and OrbiMed Advisors. Other unspecified investors also participated in the round. Treeline Biosciences plans to utilize the recent USD 421. 78 mn in venture funding raised in October 2024 to advance its product pipeline and expand market reach.

The company is focused on launching new therapeutics designed for cancer treatment, targeting specific global markets in North America and Europe by the end of 2025. These initiatives are expected to enhance research and development capabilities and facilitate strategic partnerships. The company will use the funding to initiate clinical trials for three investigational cancer therapies and advance their development toward potential patient use.